Two types of XXXX : further arguments from a study on prognosis.

@entity1 @entity64 @entity8994 @entity101 @entity6249 @entity75 @entity11524 @entity1188 @entity10334
BACKGROUND AND PURPOSE: Earlier, we found that @entity64 @entity1 with > or =1 asymptomatic @entity1188 on CT had @entity10334 and @entity101 significantly more often than @entity1 without such lesions, and we hypothesized that 2 types of @entity6249 could be distinguished during life: @entity8994 and microatheromatosis, respectively. Differences in prognosis might sustain this hypothesis of 2 @entity64 entities. Therefore, we performed a follow-up in 333 @entity1 with first @entity64 , distinguishing those with > or =1 asymptomatic @entity75 ( @entity11524 +) from those without such lesions ( @entity11524 -). METHODS: Cross-sectional follow-up was performed after 785+/-479 days (mean+/-SD) in 104 @entity11524 + @entity1 and 865+/-545 days in 229 @entity11524 - @entity1 . RESULTS: Mortality at the end of follow-up was 33% in @entity11524 + and 21% in @entity11524 - @entity1 [odds ratio (OR), 1.74; 95% confidence interval (CI), 1.01 to 3.01]. @entity64 recurrence rate was 21% in @entity11524 + and 11% in @entity11524 - (OR, 2.09; 95% CI, 1.08 to 4.06). Forty percent of @entity11524 + and 26% of @entity11524 - @entity1 had unfavorable outcome at the end of follow-up (OR, 1.95; 95% CI, 1.17 to 3.26). Kaplan-Meier curves showed less favorable survival in @entity11524 + (log-rank test, P=0.0218) and survival free of @entity64 (log-rank test, P=0.0121) than in @entity11524 -. When we restricted the analysis to @entity1 with both @entity75 and @entity10334 (n=63) compared with those without (n=196), differences were even more pronounced. CONCLUSIONS: Prognosis for mortality, recurrent @entity64 , and overall functional outcome in @entity64 @entity1 with > or =1 silent @entity75 is more unfavorable than in @entity1 without such lesions. These findings sustain the idea of 2 @entity64 entities.
